One such agent is navitoclax (ABT-263), which targets BCL-2 and BCL-XL proteins, though its clinical utility has been limited by thrombocytopenia due to platelet dependence on BCL-XL [84]. The gene discussed is BCL2L1; the disease is Thrombocytopenia.